11:55:09 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-11-06 Kvartalsrapport 2024-Q3
2024-08-22 Kvartalsrapport 2024-Q2
2024-06-06 Ordinarie utdelning AZT 0.00 NOK
2024-06-05 Årsstämma 2024
2024-05-08 Kvartalsrapport 2024-Q1
2024-02-01 Bokslutskommuniké 2023
2023-11-02 Kvartalsrapport 2023-Q3
2023-08-17 Kvartalsrapport 2023-Q2
2023-06-07 Ordinarie utdelning AZT 0.00 NOK
2023-06-06 Årsstämma 2023
2023-05-04 Kvartalsrapport 2023-Q1
2023-02-02 Bokslutskommuniké 2022
2022-10-27 Kvartalsrapport 2022-Q3
2022-08-18 Kvartalsrapport 2022-Q2
2022-06-23 Årsstämma 2022
2022-05-27 Ordinarie utdelning AZT 0.00 NOK
2022-04-28 Kvartalsrapport 2022-Q1
2022-01-27 Bokslutskommuniké 2021
2021-10-28 Kvartalsrapport 2021-Q3
2021-08-19 Kvartalsrapport 2021-Q2
2021-05-21 Ordinarie utdelning AZT 0.00 NOK
2021-05-20 Årsstämma 2021
2021-04-22 Kvartalsrapport 2021-Q1
2021-01-28 Bokslutskommuniké 2020
2020-10-22 Kvartalsrapport 2020-Q3
2020-08-19 Kvartalsrapport 2020-Q2
2020-05-15 Ordinarie utdelning AZT 0.00 NOK
2020-05-14 Årsstämma 2020
2020-04-23 Kvartalsrapport 2020-Q1
2020-01-30 Bokslutskommuniké 2019
2020-01-06 Extra Bolagsstämma 2020
2019-10-24 Kvartalsrapport 2019-Q3
2019-08-15 Kvartalsrapport 2019-Q2
2019-05-16 Ordinarie utdelning AZT 0.00 NOK
2019-05-15 Årsstämma 2019
2019-04-30 Kvartalsrapport 2019-Q1
2019-01-30 Bokslutskommuniké 2018
2018-10-18 Kvartalsrapport 2018-Q3
2018-08-16 Kvartalsrapport 2018-Q2
2018-05-09 Ordinarie utdelning AZT 0.00 NOK
2018-05-07 Årsstämma 2018
2018-04-26 Kvartalsrapport 2018-Q1
2018-02-01 Bokslutskommuniké 2017
2017-10-19 Kvartalsrapport 2017-Q3
2017-08-17 Kvartalsrapport 2017-Q2
2017-05-12 Ordinarie utdelning AZT 0.00 NOK
2017-05-11 Årsstämma 2017
2017-04-27 Kvartalsrapport 2017-Q1
2017-02-02 Bokslutskommuniké 2016
2016-10-26 Kvartalsrapport 2016-Q3
2016-08-17 Kvartalsrapport 2016-Q2
2016-05-12 Ordinarie utdelning AZT 0.00 NOK
2016-05-11 Årsstämma 2016
2016-04-19 Kvartalsrapport 2016-Q1
2016-02-11 Bokslutskommuniké 2015
2016-02-11 Kapitalmarknadsdag 2016
2015-11-03 Kvartalsrapport 2015-Q3
2015-08-13 Kvartalsrapport 2015-Q2
2015-05-13 Ordinarie utdelning AZT 0.00 NOK
2015-05-12 Årsstämma 2015
2015-05-05 Kvartalsrapport 2015-Q1
2015-02-17 Bokslutskommuniké 2014
2014-11-05 Kvartalsrapport 2014-Q3
2014-08-13 Kvartalsrapport 2014-Q2
2014-05-15 Ordinarie utdelning AZT 0.00 NOK
2014-05-14 Årsstämma 2014
2014-04-30 Kvartalsrapport 2014-Q1
2014-02-14 Bokslutskommuniké 2013
2013-11-01 Kvartalsrapport 2013-Q3
2013-08-09 Kvartalsrapport 2013-Q2
2013-06-13 Kapitalmarknadsdag 2013
2013-05-28 Ordinarie utdelning
2013-05-27 Årsstämma 2013
2013-05-07 Kvartalsrapport 2013-Q1
2013-02-01 Extra Bolagsstämma 2013
2013-01-07 Bokslutskommuniké 2012
2012-11-06 Kvartalsrapport 2012-Q3
2012-08-10 Kvartalsrapport 2012-Q2
2012-05-07 Ordinarie utdelning AZT 0.00 NOK
2012-05-07 Årsstämma 2012
2012-05-07 Kvartalsrapport 2012-Q1
2012-02-21 Bokslutskommuniké 2011
2011-11-08 Kvartalsrapport 2011-Q3
2011-08-10 Kvartalsrapport 2011-Q2
2011-05-13 Kvartalsrapport 2011-Q1
2011-05-13 Årsstämma 2011
2011-05-12 Ordinarie utdelning
2011-02-17 Bokslutskommuniké 2010
2010-11-12 Kvartalsrapport 2010-Q3
2010-08-10 Kvartalsrapport 2010-Q2
2010-05-11 Kvartalsrapport 2010-Q1
2010-05-04 Årsstämma 2010
2010-03-03 Bokslutskommuniké 2009

Beskrivning

LandNorge
ListaOB Match
SektorHälsovård
IndustriBioteknik
ArcticZymes Technologies är verksamma inom bioteknik. Bolaget specialiserar sig inom forskning och utveckling av läkemedel för behandling av autoimmuna sjukdomar. Störst inriktning återfinns inom utveckling av glukaner, framtagande av immunstimulerande medel, samt analys av enzymer. Visionen är att testa och utveckla medicinen för att sedan föra vidare dessa i användning för RNA och DNA processer. Bolaget gick tidigare under namnet Biotec Pharmacon och har sitt huvudkontor i Tromsö.
2021-12-22 09:29:49

Tromsø, Norway, 22[nd] December 2021 - ArcticZymes Technologies ASA (OSE: AZT) announces the launch of new products and opening of the new production facility

ArcticZymes technologies launches the following products:
  • ArcticZymes R2D[TM] Ligase - Patent pending ligase with novel specificity enabling the ligation of DNA to both ends of RNA using a DNA splint. The enzyme is an enabling tool for new technology development and is expected to have broad applicability in Molecular Diagnostics (MDx), Next Generation Sequencing (NGS), and gene/RNA synthesis applications for potential therapeutic applications.

  • IsoPol[®] BST[+] High Concentration Glycerol FREE - highly concentrated formulation of the DNA polymerase to support ongoing customer opportunities for utility in new NGS platform technologies and Point-of-Care diagnostic test developments.

  • M-SAN HQ ELISA kit - The new ELISA immunoassay product is an essential support product for customers using the M-SAN HQ enzyme in biomanufacturing processes for gene therapy and viral vaccine production. In combination with the M-SAN HQ enzyme, the new immunoassay product provides a complete solution for the critical elimination of DNA contamination during biomanufacturing.

  • M-SAN HQ enzyme (Upscaled) - The upscaling of M-SAN HQ enzyme was timed to coincide with the launch of the new ELISA kit. The M-SAN HQ enzyme manufacturing process has been upscaled and transitioned to large-scale fermentation. This successful upscaling achieved greater than a 100-fold increase in fermentation yield. The upscaling was necessary to meet the expected increase in demand following the launch of the ELISA kit and ensure customers can receive large quantities of enzyme from a single production batch.

The ArcticZymes R2D[TM] Ligase and M-SAN HQ products will be available in our warehouses during January 2022. The IsoPol[®] BST[+] High Concentration Glycerol FREE product will be available during February 2022.

Furthermore, ArcticZymes Technologies is proud to announce the opening of its new 500 m[2] production facility at the SIVA Innovation Centre in Tromsø. The new state of the art facility caters for the scalable manufacturing of enzyme products and meets the strict requirements demanded by ISO13485: In Vitro Diagnostics (IVD) and cGMP. The facility has the capacity to support the increasing production demands of existing products, future innovations, and organic growth of the business over the next 4-5 years. Lastly all Tromsø based employees are now located under one roof at the SIVA Innovation Centre.

ArcticZymes Technologies ASA, CEO, Jethro Holter said:

"It is a proud day for ArcticZymes Technologies and its employees to bring new innovations to its customers.

We are delighted with the new production facilitates and inspired by the prospect they will be instrumental in supporting future organic growth."

For more information, please contact:

ArcticZymes Technologies
CEO, Jethro Holter Tel: +47 46 85 91 46
CFO, Børge Sørvoll Tel: +47 95 29 01 87
ir@arcticzymes.com

About ArcticZymes Technologies ASA

ArcticZymes Technologies is a Norwegian life sciences company focused on the development, manufacturing and commercialization of novel recombinant enzymes for use in molecular research, In Vitro Diagnostics (IVD) and therapeutics.

Listed on the Oslo Stock Exchange since 2005 originally under the [Biotec] ticker, as Biotec Pharmacon. The company rebranded as ArcticZymes Technologies in 2020 under the [AZT] ticker. Its headquarters are based in Tromsø, Norway, at the SIVA Innovation Centre.

ArcticZymes Technologies' IP and capabilities are protected via a large portfolio of patents.

For more information, please visit the website: www.arcticzymes.com.